textabstractThe 5-hydroxytryptamine (5-HT) receptor family mediates the effects of several drugs highly effective in migraine primarily by activating 5-HT 1B, 5-HT1D, and 5-HT1F receptors. Ergotamine, dihydroergotamine, and methysergide, as well as the "triptan" sumatriptan, are all agonists for these receptors. The receptor profile and degree of selectivity of these four drugs differ, which is reflected by their side effects that limit their use in the acute and prophylactic treatment of migraine. The acute antimigraine efficacy of these remedies is very much dependent on the formulation used where, in general, parenteral formulations are more effective in reliving the symptoms of a migraine attack
Research for a new antimigraine compound started at Glaxo in 1972 and led to the discovery of the fi...
Introduction: Migraine is one of the most common neurological disorders. Nowadays, the 5-HT1B/1D rec...
Migraine is a multifactorial and disabling syndrome often in comorbidity with psychiatric illnesses....
The 5-hydroxytryptamine (5-HT) receptor family mediates the effects of several drugs highly effectiv...
The 5-hydroxytryptamine (5-HT) receptor family mediates the effects of several drugs highly effectiv...
Migraine is one of the most prevalent disorders seen in clinical practice today and also a major cau...
In the past 10 years, there have been great advances in the understanding of the pathophysiology of ...
In the past 10 years, there have been great advances in the understanding of the pathophysiology of ...
textabstractMigraine is a recurrent incapacitating neurovascular disorder characterized by unilatera...
textabstractMigraine is a neurovascular disorder that involves activation of the trigeminovascular s...
In 1996, our knowledge of acute antimigraine therapy expanded in three major areas. First, large sur...
Migraine is a neurovascular disorder that involves activation of the trigeminovascular system and cr...
Research for a new antimigraine compound started at Glaxo in 1972 and led to the discovery of the fi...
Migraine is a multifactorial chronic central nervous system disorder, characterized by recurrent dis...
Harold Wolff’s theory of vasodilation in migraine is well-known. Less known is his search for a peri...
Research for a new antimigraine compound started at Glaxo in 1972 and led to the discovery of the fi...
Introduction: Migraine is one of the most common neurological disorders. Nowadays, the 5-HT1B/1D rec...
Migraine is a multifactorial and disabling syndrome often in comorbidity with psychiatric illnesses....
The 5-hydroxytryptamine (5-HT) receptor family mediates the effects of several drugs highly effectiv...
The 5-hydroxytryptamine (5-HT) receptor family mediates the effects of several drugs highly effectiv...
Migraine is one of the most prevalent disorders seen in clinical practice today and also a major cau...
In the past 10 years, there have been great advances in the understanding of the pathophysiology of ...
In the past 10 years, there have been great advances in the understanding of the pathophysiology of ...
textabstractMigraine is a recurrent incapacitating neurovascular disorder characterized by unilatera...
textabstractMigraine is a neurovascular disorder that involves activation of the trigeminovascular s...
In 1996, our knowledge of acute antimigraine therapy expanded in three major areas. First, large sur...
Migraine is a neurovascular disorder that involves activation of the trigeminovascular system and cr...
Research for a new antimigraine compound started at Glaxo in 1972 and led to the discovery of the fi...
Migraine is a multifactorial chronic central nervous system disorder, characterized by recurrent dis...
Harold Wolff’s theory of vasodilation in migraine is well-known. Less known is his search for a peri...
Research for a new antimigraine compound started at Glaxo in 1972 and led to the discovery of the fi...
Introduction: Migraine is one of the most common neurological disorders. Nowadays, the 5-HT1B/1D rec...
Migraine is a multifactorial and disabling syndrome often in comorbidity with psychiatric illnesses....